Verve Therapeutics Inc

NASDAQ:VERV   1:31:15 PM EDT
21.33
-0.78 (-3.53%)
Earnings Announcements

Verve Therapeutics Provides Regulatory Update On Verve-101 And Reports Q3 Financial Results

Published: 11/07/2022 12:02 GMT
Verve Therapeutics Inc (VERV) - Verve Therapeutics Inc Q3 Loss per Share $0.79.
Verve Therapeutics Provides Regulatory Update on Verve-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial Results.
Verve Therapeutics Inc - Well-capitalized With $550.7 Million Supporting Runway Into Second Half of 2025.
Verve Therapeutics Inc - Verve-101 Investigational New Drug Application Placed on Hold by U.S. Food and Drug Administration.
Verve Therapeutics Inc - Dosing Completed in First Dose Cohort of Heart-1 Clinical Trial of Verve-101 in Patients With Hefh.
Verve-will Provide Updates Pending Engagement With FDA,to Work Closely With FDA to Resolve Hold As Promptly As Possible to Initiate Dosing in Us.
Revenue is expected to be $0.3 Million
Adjusted EPS is expected to be -$0.75

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.76

More details on our Analysts Page.